Abstract 1296P
Background
Our phase 2 trial was the first to report the efficacy and safety of neoadjuvant chemo-free regimen with camrelizumab and apatinib in patients with resectable non-small-cell lung cancer (NSCLC), showing promising pathologic responses and manageable toxicity. Here, we aimed to report 1-year event-free survival (EFS) and updated safety data from the above trial.
Methods
Treatment-naïve patients with histologically confirmed resectable stage IIA-IIIB NSCLC (stage IIIB, T3N2 only) and ECOG performance status of 0 or 1 received three cycles of camrelizumab (200 mg, i.v., q2w) and apatinib (250 mg, orally, qd, for 5 days followed by 2 days off), followed by surgery after 3-4 weeks. This analysis including EFS (a prespecified secondary endpoint) and updated safety was performed after an extended follow-up from the preliminary analysis.
Results
Between November 9, 2020 and February 16, 2022, 78 patients were enrolled and treated. With a median follow-up of 19.4 months (95% CI 18.0-20.5), the median EFS was not reached (95% CI 23.2-not reached). The 6- and 12-month EFS rates were 89.4% (95% CI 79.8-94.5) and 82.3% (95% CI 71.4-89.3), respectively. The EFS rates at 6 months and 12 months in the subgroups are presented in the Table. Seventy-one (91.0%) of the 78 patients experienced at least one treatment-related adverse event (TRAE) of any grade, of which grade 3 or above TRAEs were observed in six (7.7%) patients. No new safety signal was observed. Table: 1296P
| Subgroup | Patients (n = 78), n (%) | 6-month EFS rate, % (95% CI) | 12-month EFS rate, % (95% CI) |
| Overall | 78 (100) | 89.4 (79.8-94.5) | 82.3 (71.4-89.3) |
| Disease stage | |||
| II | 38 (48.7) | 94.5 (79.8-98.6) | 86.2 (69.9-94.0) |
| III | 40 (51.3) | 84.5 (68.7-92.8) | 78.7 (61.8-88.8) |
| PD-L1 expression | |||
| <1% | 35 (55.6) | 85.3 (68.2-93.6) | 76.2 (57.9-87.3) |
| ≥1% | 28 (44.4) | 92.9 (74.3-98.2) | 85.4 (65.7-94.3) |
| Histologic type | |||
| Squamous cell carcinoma | 59 (75.6) | 91.2 (80.2-96.2) | 84.1 (71.6-91.4) |
| Adenocarcinoma | 19 (24.4) | 83.9 (57.9-94.5) | 76.9 (49.0-90.8) |
Conclusions
The extended follow-up data shows continued benefits and a manageable safety profile with neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer.
Clinical trial identification
ChiCTR2000033588.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1265P - Toripalimab plus chemotherapy as neoadjuvant treatment for resectable stage IIB-IIIB NSCLC (RENAISSANCE study): A single-arm, phase II trial
Presenter: Shi Yan
Session: Poster session 04
1266P - Prediction of lung cancer risk in ground-glass nodules using deep learning from CT images
Presenter: Anil Vachani
Session: Poster session 04
1267P - Enhancing pulmonary nodule diagnosis: A combinatorial model of cfDNA methylation, plasma proteins and LDCT imaging
Presenter: Meng Yang
Session: Poster session 04
1268P - Liquid biopsy and CT-based multi-omics fusion enhances differential diagnosis of early-stage lung adenocarcinoma
Presenter: Yanwei Zhang
Session: Poster session 04
1269P - Machine learning model for predicting lung cancer recurrence after surgical treatment: A retrospective study using NLST and European hospital data
Presenter: Ann Valter
Session: Poster session 04
1272P - Postoperative survival prediction in non-small cell lung cancer patients based on driver genotypes
Presenter: Huiting Wang
Session: Poster session 04
1273P - The prognostic value evaluation of a tissue Comprehensive Genomic Profiling (CGP)-informed personalized MRD detection assay in NSCLC
Presenter: Wei Gao
Session: Poster session 04
1274P - Early dynamics of circulating tumor DNA following curative hypofractionated radiotherapy related to disease control in lung cancer
Presenter: Kyungmi Yang
Session: Poster session 04
1275P - Genomic analysis of lung adenocarcinoma with micropapillary component: Identification of micropapillary-related subtypes and development of a prognostic model
Presenter: Yuechun Lin
Session: Poster session 04